Open access to integrated pharmacological data

Currently, pharmaceutical companies assemble their own in-house databases of pharmacological and physicochemical data resources. Open PHACTS integrates data from multiple publicly-available databases, giving you access to a vast linked data resource through a stable, integrated infrastructure. This allows researchers to build better analysis pipelines — and gives researchers in academia and smaller companies unprecedented access […]

Sigma-Aldrich Introduces the MyriaScreen Diversity Collection for Drug Discovery

TimTec and Sigma-Aldrich (NASDAQ:SIAL) are pleased to announce the availability of the MyriaScreen Diversity Collection of drug-like screening compounds produced in collaboration, as a result of careful evaluation, filtering, and refinement of selections from each of our screening compound collections. The MyriaScreen Diversity Collection is comprised of 10,000 high-purity screening compounds handpicked to maximize chemical […]

BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma

SAN DIEGO, Aug. 10 /PRNewswire/ — BrainCells Inc. (BCI) today announced it has in-licensed a clinical-stage compound from Mitsubishi Pharma Corp. (MPC) that BCI will reposition and develop for the treatment of central nervous system (CNS) diseases, including mood disorders. MPC extensively developed the compound for another CNS indication, then suspended the program when the […]

Savient Pharmaceuticals Initiates Patient Dosing for Puricase(R) Phase 3 Clinical Study; Company on track for BLA filing in late 2007

Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) a specialtypharmaceutical company engaged in developing, manufacturing, andmarketing pharmaceutical products that address unmet medical needs,announced today that it has dosed the first patient in its Phase 3clinical studies of Puricase(R), (PEG-uricase) for the treatment ofpatients with symptomatic gout for whom conventional therapy iscontraindicated or has been ineffective.The two, replicate Phase 3 […]

Proteins’ ‘jiggle’ may give a jolt. Penn finding could be huge for drugmakers.

In a discovery that could have sweeping implications for pharmaceuticals of the future, scientists are reporting today that the long-observed jiggle of proteins is not just nervous energy but a carefully orchestrated dance that brings them together. Virtually all medicines work by interacting with proteins – tiny organic molecules that trigger all bodily functions, from […]

Ruga Licenses Selexagen’s RAF Kinase Program for Targeted Cancer Therapy

Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Cancers are of many kinds and also are the differenttreatments for cancer. Thetype of treatment that your doctor will suggest is dependent on the […]

Janssen Reports Positive Phase III Data for Chronic Diabetic Peripheral Neuropathy Analgesic

Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN. Diabetes is a common condition but it is a slow killer. […]

Chemie Uzbekistan 2011

The 5th Anniversary Central Asian International exhibition «Chemical industry – Chemie Uzbekistan» and the 2nd Uzbek International exhibition of plastics and rubber – «Plastex Uzbekistan 2011» will be held from the 16th till the 18th of November 2011, at the Pavilion 1 of OJSS «Uzexpocentre». “ITE UZBEKISTAN” is the organizer of the exhibitions Talking about […]